{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T06:09:59Z","timestamp":1783490999158,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005725","name":"CHDI Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.parkreldis.2021.01.010","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T14:40:38Z","timestamp":1610635238000},"page":"56-62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Estimating the causal effects of modifiable, non-genetic factors on Huntington disease progression using propensity score weighting"],"prefix":"10.1016","volume":"83","author":[{"given":"Beth Ann","family":"Griffin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2167-4878","authenticated-orcid":false,"given":"Marika Suttorp","family":"Booth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Busse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J.","family":"Wild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Setodji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Warner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Sampaio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrita","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.parkreldis.2021.01.010_bib1","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/ng0893-398","article-title":"The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease","volume":"4","author":"Andrew","year":"1993","journal-title":"Nat. Genet."},{"issue":"5","key":"10.1016\/j.parkreldis.2021.01.010_bib2","first-page":"1202","article-title":"The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size","volume":"60","author":"Brinkman","year":"1997","journal-title":"Am. J. Hum. Genet."},{"issue":"4","key":"10.1016\/j.parkreldis.2021.01.010_bib3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/ng0893-387","article-title":"Trinucleotide repeat length instability and age of onset in Huntington's disease","volume":"4","author":"Duyao","year":"1993","journal-title":"Nat. Genet."},{"issue":"2","key":"10.1016\/j.parkreldis.2021.01.010_bib4","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ajmg.b.30992","article-title":"CAG\u2010repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches","volume":"153","author":"Langbehn","year":"2010","journal-title":"Am. J. Med. Genet. Part B: Neuropsychiatric Genetics"},{"issue":"4","key":"10.1016\/j.parkreldis.2021.01.010_bib5","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/ng0893-393","article-title":"Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease","volume":"4","author":"Snell","year":"1993","journal-title":"Nat. Genet."},{"issue":"10","key":"10.1016\/j.parkreldis.2021.01.010_bib6","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1073\/pnas.0308679101","article-title":"Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset","volume":"101","author":"Wexler","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"issue":"11","key":"10.1016\/j.parkreldis.2021.01.010_bib7","first-page":"1382","article-title":"Relationship of Mediterranean diet and caloric intake to phenoconversion in Huntington disease","volume":"70","author":"Marder","year":"2013","journal-title":"JAMA Neurol."},{"issue":"2","key":"10.1016\/j.parkreldis.2021.01.010_bib8","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0022-510X(87)90164-X","article-title":"Which factors influence age at onset and rate of progression in Huntington's disease?","volume":"80","author":"Buruma","year":"1987","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.parkreldis.2021.01.010_bib9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.nbd.2013.05.013","article-title":"Association between caffeine intake and age at onset in Huntington's disease","volume":"58","author":"Simonin","year":"2013","journal-title":"Neurobiol. Dis."},{"issue":"3","key":"10.1016\/j.parkreldis.2021.01.010_bib10","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/mds.27239","article-title":"Selected health and lifestyle factors, cytosine\u2010adenine\u2010guanine status, and phenoconversion in Huntington's disease","volume":"33","author":"Tanner","year":"2018","journal-title":"Mov. Disord."},{"issue":"8","key":"10.1016\/j.parkreldis.2021.01.010_bib11","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1002\/mds.23385","article-title":"What is the impact of education on Huntington's disease?","volume":"26","author":"L\u00f3pez\u2010Send\u00f3n","year":"2011","journal-title":"Mov. Disord."},{"issue":"10","key":"10.1016\/j.parkreldis.2021.01.010_bib12","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/mds.23108","article-title":"A retrospective study of the impact of lifestyle on age at onset of Huntington disease","volume":"25","author":"Trembath","year":"2010","journal-title":"Mov. Disord."},{"issue":"8","key":"10.1016\/j.parkreldis.2021.01.010_bib13","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1001\/archneur.1991.00530200036015","article-title":"Factors associated with slow progression in Huntington's disease","volume":"48","author":"Myers","year":"1991","journal-title":"Arch. Neurol."},{"issue":"9","key":"10.1016\/j.parkreldis.2021.01.010_bib14","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1007\/s00415-012-6415-8","article-title":"Substance abuse may be a risk factor for earlier onset of Huntington disease","volume":"259","author":"Byars","year":"2012","journal-title":"J. Neurol."},{"issue":"9","key":"10.1016\/j.parkreldis.2021.01.010_bib15","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1212\/WNL.0000000000003661","article-title":"Substance abuse may hasten motor onset of Huntington disease Evaluating the Enroll-HD database","volume":"88","author":"Schultz","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2021.01.010_bib16","series-title":"Enroll-HD: A Prospective Registry Study in a Global Huntington's Disease Cohort","author":"Landwehrmeyer","year":"2012"},{"issue":"2","key":"10.1016\/j.parkreldis.2021.01.010_bib17","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.psychres.2010.04.030","article-title":"Earliest functional declines in Huntington disease","volume":"178","author":"Beglinger","year":"2010","journal-title":"Psychiatr. Res."},{"issue":"15","key":"10.1016\/j.parkreldis.2021.01.010_bib18","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1002\/mds.23337","article-title":"Challenges assessing clinical endpoints in early Huntington disease","volume":"25","author":"Paulsen","year":"2010","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.parkreldis.2021.01.010_bib19","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.29.1.1","article-title":"Huntington disease: clinical care and evaluation","volume":"29","author":"Shoulson","year":"1979","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.parkreldis.2021.01.010_bib20","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.psychres.2010.04.030","article-title":"Earliest functional declines in Huntington disease","volume":"178","author":"Beglinger","year":"2010","journal-title":"Psychiatr. Res."},{"issue":"2","key":"10.1016\/j.parkreldis.2021.01.010_bib21","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/mds.870110204","article-title":"Unified Huntington's disease rating scale: reliability and consistency","volume":"11","year":"1996","journal-title":"Mov. Disord."},{"issue":"9","key":"10.1016\/j.parkreldis.2021.01.010_bib22","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S1474-4422(17)30161-8","article-title":"Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study","volume":"16","author":"Moss","year":"2017","journal-title":"Lancet Neurol."},{"issue":"24","key":"10.1016\/j.parkreldis.2021.01.010_bib23","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1212\/WNL.0000000000004743","article-title":"Motor, cognitive, and functional declines contribute to a single progressive factor in early HD","volume":"89","author":"Schobel","year":"2017","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.parkreldis.2021.01.010_bib24","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/rssb.12027","article-title":"Covariate balancing propensity score","volume":"76","author":"Imai","year":"2014","journal-title":"J. Roy. Stat. Soc. B"},{"key":"10.1016\/j.parkreldis.2021.01.010_bib25","first-page":"523","article-title":"Demystifying double robustness: a comparison of alternative strategies for estimating a population mean from incomplete data","author":"Kang","year":"2007","journal-title":"Stat. Sci."},{"issue":"3","key":"10.1016\/j.parkreldis.2021.01.010_bib26","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.nbd.2008.01.015","article-title":"Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease","volume":"30","author":"Duan","year":"2008","journal-title":"Neurobiol. Dis."},{"issue":"8","key":"10.1016\/j.parkreldis.2021.01.010_bib27","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1111\/j.1460-9568.2005.04365.x","article-title":"Cognitive disorders and neurogenesis deficits in Huntington's disease mice are rescued by fluoxetine","volume":"22","author":"Grote","year":"2005","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.parkreldis.2021.01.010_bib28","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejphar.2015.10.033","article-title":"Antidepressants for neuroprotection in Huntington's disease: a review","volume":"769","author":"Jamwal","year":"2015","journal-title":"Eur. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.parkreldis.2021.01.010_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022133","article-title":"Sexually dimorphic serotonergic dysfunction in a mouse model of Huntington's disease and depression","volume":"6","author":"Renoir","year":"2011","journal-title":"PloS One"},{"issue":"2","key":"10.1016\/j.parkreldis.2021.01.010_bib30","first-page":"167","article-title":"Modulation by serotonin of glutamate-induced lethality in mice","volume":"74","author":"Kamei","year":"1991","journal-title":"Res. Commun. Chem. Pathol. Pharmacol."},{"issue":"3","key":"10.1016\/j.parkreldis.2021.01.010_bib31","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.arcmed.2007.11.011","article-title":"Excitotoxic neuronal death and the pathogenesis of Huntington's disease","volume":"39","author":"S\u00e1nchez","year":"2008","journal-title":"Arch. Med. Res."},{"key":"10.1016\/j.parkreldis.2021.01.010_bib32","first-page":"36","volume":"4","author":"Craufurd","year":"2014","journal-title":"Neuropsychiatr. Neuropsychol. Huntington's Dis."}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802021000262?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802021000262?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:20:48Z","timestamp":1761178848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802021000262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":32,"alternative-id":["S1353802021000262"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2021.01.010","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estimating the causal effects of modifiable, non-genetic factors on Huntington disease progression using propensity score weighting","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2021.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}